Boston, MA 04/02/2014 (wallstreetpr) – The traction in the e-commerce and discount sales business is having its positive impact on Zulily Inc (NASDAQ:ZU) as it is in many other online sales platform stocks. Having come to the scene just last year, Zulily has quickly become a leading provider of flash sales in North America. Its multi-pronged approach to this business which involves mobile and desktop sites is even making the deal quite attractive. The online retail format of combining discount sales and e-commerce has helped ZU to realize substantial growth in revenue quarter after quarter and with its strong presence in mobile platform, supported by the increasing uptake of smartphones, the trend of compelling revenue growth may have just started. Shares of Zulily Inc (NASDAQ:ZU), relying on the prospects investors continue to attach on online retail business, managed to jump almost 10 percent in the previous session, without any company-specific announcement.
Production of renewable energy is not only growing rapidly, its adoption and application is also witnessing tremendous growth. But can energy storage companies such as Maxwell Technologies Inc. (NASDAQ:MXWL) benefit from the opportunities in the renewable? MXWL is involved in the providing of energy storage as well as delivery products. The market of energy storage is regarded as a key component in the future of renewable energy. The market is projected to grow at least by 9 percent over the next several years. That simply means that MXWL and peers are in for some significant gains going forward. Maxwell Technologies Inc. (NASDAQ:MXWL)’s prospects are well taken care of in the wind energy storage where it provides smart storage solutions and technologies to ensure that excess energy generated from wind do not go to waste, but instead preserved for future needs. As prospects for energy storage companies become clearer to investors, stocks in this category are witnessing positive trading. Shares of MXWL jumped more than 11 percent in the previous session.
Arrowhead Research Corp (NASDAQ:ARWR) had its shares soaring to almost 15 percent after the clinical-stage biopharma announced completion of enrollment for the first patients cohort for the Phase 2a study of its experimental drug targeted at the treatment of hepatitis B.